Page 8 - Biocon Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biocon brings 'first-of-its-kind' programme in Global Regulatory Affairs Biocon brings 'first-of-its-kind' programme in Global Regulatory Affairs 11 May 2021 | News Image credit- shutterstock.com Biocon Academy, a CSR initiative of global biopharmaceutical company, Biocon, and a Center of Excellence for Advanced Learning in Biosciences, has introduced a new and unique programme in Global Regulatory Affairs (GRA) in collaboration with JSS Academy of Higher Education and Research (JSS AHER), Mysuru. The exclusive programme is designed to impart applied knowledge on various good regulatory p...

Biocon posts profit of ₹254 crore for Q4 April 29, 2021 Performance driven by biosimilars, research services and generics businesses Global biopharma company Biocon Limited has posted 106.50 per cent profit for the fourth quarter (Q4) of FY 2020-21 on a consolidated basis, at ₹254 crore as against ₹123 crore posted last year, driven by biosimilars, research services and generics businesses. The company’s revenues are higher by 26 per cent, at ₹2,044 crore as against ₹1,621 crore in the same period last year. The company has gained ₹160 crore arising on the fair valuation of Bic...

Biocon's revenue for the said quarter stood at Rs 2,044 crore, showing a growth of 26 per cent. Its EBITDA grew 68 per cent to Rs 641 crore in Q4 of the financial year

Read more about Biocon gains after Q4 PAT rises 105% YoY on Business Standard. Biocon rose 1.32% to Rs 396.10 after the company reported 105% jump in consolidated net profit to Rs 254 crore in Q4 FY21 from Rs 123 crore in Q4 FY20.

The company had reported profit of Rs 159.1 crore in the corresponding period a year ago. Total income of the company rose by 26.13 per cent to Rs 2,044.1 crore as against Rs 1,620.6 crore for the same period year ago, the company said in a regulatory filing. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, said: "In Q4FY21 our revenues grew 26 per cent year-on-year to Rs 2,044 crore driven by our biosimilars, research services and generics businesses". Mazumdar-Shaw said the Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb. "Syngene through...